Skip to content

The Co-creation and Feasibility of a Compassion Training as a Follow-up to Mindfulness-Based Cognitive Therapy in Patients with Recurrent Depression.

Rhoda Schuling, Marloes J. Huijbers, Hetty Jansen, Renée Metzemaekers, Erik Van den Brink, Frits Koster, Hiske Van Ravesteijn, Anne E. M. Speckens

Mindfulness 2018 DOI: 10.1007/s12671-017-0783-1 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Uncontrolled feasibility study with qualitative focus groups Randomized Peer reviewed
Sample size 17
Population Adults with recurrent depression who had previously participated in Mindfulness-Based Cognitive Therapy; 15 females and 2 males aged 37 to 71
Intervention Mindfulness-Based Compassionate Living (MBCL)
Duration Eight-session program
Topics Meditation Depression
Keywords Co-creation Qualitative study Recurrent depression Self-compassion
Key findings MBCL appears feasible and acceptable as a follow-up to MBCT, with no dropouts and high attendance (average 7.52 of 8 sessions). Depressive symptoms decreased in the second group but not the first, self-compassion increased in both groups, and worry and overall mindfulness did not change. The authors note possible selection bias and call for a randomized controlled trial.

Abstract

The aim of this study was to assess the feasibility, acceptability and preliminary effectiveness of Mindfulness - Based Compassionate Living (MBCL) as a follow-up intervention to Mindfulness Based Cognitive Therapy in adults with recurrent depression. We conducted an uncontrolled study in 17 patients with recurrent depression, in two successive groups. The first group contained novices to compassion training (N = 14); in the second group, ten of these participated again, in addition to three new participants (N = 13). The overall group contained 15 females and 2 males, aged between 37 and 71. The MBCL program was qualitatively evaluated using post-intervention focus group interviews in both groups. In addition, self-report questionnaires assessing depressive symptoms, worry and both self-compassion and mindfulness skills were administered before and after MBCL. No patients dropped out of the intervention. Average attendance was 7.52 (SD 0.73) out of eight sessions. Helpful elements were theory on the emotion regulation systems, practicing self-compassion explicitly and embodiment of a compassionate attitude by the teachers. Unhelpful elements were the lack of a clear structure, lack of time to practice compassion for self and the occurrence of the so-called back draft effect. We adapted the program in accordance with the feedback of the participants. Preliminary results showed a reduction in depressive symptoms in the second group, but not in the first group, and an increase in self-compassion in both groups. Worry and overall mindfulness did not change. MBCL appears to be feasible and acceptable for patients suffering from recurrent depressive symptoms who previously participated in MBCT. Selection bias may have been a factor as only experienced and motivated participants were used; this, however, suited our intention to co-create MBCL in close collaboration with knowledgeable users. Examination of the effectiveness of MBCL in a sufficiently powered randomised controlled trial is needed.

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Explore topics